The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter 
Professionals >> Visit The Body PROThe Body en Espanol
Ask the Experts About

Choosing Your MedsChoosing Your Meds
Rollover images to visit our other forums!
  • Email Email
  • Glossary Glossary

Oct 6, 2003

Why don't you ever hear anything about Rescriptor? It is an approved NNRTI but no one ever mentions it. Is anyone on this drug?

Response from Dr. Pierone

The reason that this medication is not often mentioned is that it used very much anymore. It is easier to use nevirapine (Viramune) or efavirenz (Sustiva) in the NNRTI class. Rescriptor is 6 pills per day (3 - 200mg tablets twice daily) and competes against one Sustiva or two Viramune a day.

Also, if someone develops resistance to Viramune or Sustiva they usually develop cross-resistance to Rescriptor even though they had never been exposed to Rescriptor. This limits its use in a salvage scenario. We used to use Resciptor with Crixivan in the past because of an interaction that led to higher levels of Crixivan.

Having said this, I still have a few patients on it (from the olden days) and they are doing well. They have undetectable viral load, have their medicine-taking routine down, and don't want to rock the boat and risk exposure to an alternative medication.

When to start meds
ALC count

  • Email Email
  • Glossary Glossary



This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint